Research Study

A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)
Principal Investigator 
Kim Nguyen Chi

Overview

Body Locations and Systems 
Prostate Cancer
Disorders and Conditions 
Cancers
ClinicalTrials.gov# 
NCT01715285
Status 
Closed to Recruitment
Study Start/End 
Oct 1, 2013 to Jul 1, 2018
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Maureen Palmer, Research Coordinator
Phone 
604-875-5675
Purpose of Study 

The purpose of this study is to determine if newly diagnosed (within previous 3 months) participants with metastatic (spread of cancer cells from one part of the body to another ) hormone-naive prostate cancer (mHNPC) who have high-risk prognostic factors will benefit from the addition of abiraterone acetate and low-dose prednisone to androgen deprivation therapy (ADT; lutenizing hormone releasing hormone [LHRH] agonists or surgical castration).


 

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.